Safety, Efficacy of Oral Microbiome Therapeutic Confirmed in Recurrent CDI Study
The investigational oral microbiome therapeutic SER-109 was found to be safe and effective for the prevention of recurrent CDI.
The investigational oral microbiome therapeutic SER-109 was found to be safe and effective for the prevention of recurrent CDI.
The vaccine candidate contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with an adjuvant.